Healthcare Providers
Publications & Presentations
Access manuscripts, posters, and presentations across our research programs and areas of scientific interest.
The Latest Evidence from Scientific Meetings & Publications
Phase 3 Trial Design and Methodology: Treatment with DT120 (Lysergide) in Generalized Anxiety Disorder (GAD) & Major Depressive Disorder (MDD)
Phase 3 Topline Results of DT120 (Lysergide) in Major Depressive Disorder
Phase 3 Topline Results of DT120 (Lysergide) in Generalized Anxiety Disorder
DT120 (Lysergide) Safety Profile From Phase 1 and Phase 2 Clinical Studies
DT120 for Major Depressive Disorder: Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
Suicidal Ideation Frequency Across Generalized Anxiety Disorder, Major Depressive Disorder, and Comorbid Cohorts: The Role of Symptom Severity, Diagnosis, and Undetected Disorder Burden
Single Treatment with MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial
Robison R, Barrow R, Conant C, et al.
Treatment Instability in Generalized Anxiety Disorder (GAD): A U.S. Real-World Evidence Study
Louie D, Ferries E, Suponcic S, et al.
The medical information on this site is intended for U.S. healthcare professionals. The information is provided for medical educational purposes and is not intended to be promotional nor provide medical advice. Content may include information about products and uses that are not approved by the US Food and Drug Administration (FDA). Healthcare professionals should use independent judgment in applying information to their medical practice.